"Our studies indicate that provided those structures are properly modified to be made biocompatible, toxicity levels should be tolerable. This automatically opens up the door for the development of carbon nanostructure-based pharmaceuticals," said researcher Kostas Kostarelos, a pharmaceutical nanotechnology expert at the University of London's School of Pharmacy.